The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse ...

IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...

Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial, Conduit Pharmaceuticals is tapping Charles ...

Financial writer discusses Coya Therapeutics, Inc.'s Treg therapies for neurodegenerative diseases like ALS, FTD, and PD.

Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...

Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice. The novel drug CT-179 was ...

Scientists at The Hospital for Sick Children (SickKids) have discovered a way to stop tumor growth before it starts for a ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled SAN FRANCISCO and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., ...

WVU has formed a strategic partnership with GATC Health Corp, a tech-bio company that uses artificial intelligence to ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.

An open-label extension phase showed that 77.8% of ... product candidates, research pipeline, ongoing and currently planned preclinical studies and clinical trials, regulatory submissions and ...

GH001 led to a significant reduction from baseline of -15.2 points in Montgomery-Åsberg Depression Rating Scale (MADRS) total score on Day 8, compared with +0.3 points in the placebo group (difference ...